PubMed Health⌕ Search

Biomedical subjects

H De Wulf

Publications and source records attributed to H De Wulf.

At least 19 recordsLinked to original sources
PubMed1995

Some P2 purinergic agonists increase cytosolic calcium but not inositol 1,4,5-trisphosphate in isolated rat hepatocytes.

Based on the capacity to increase IP3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists can be subdivided into two classes: ATP, ADP, UTP, 2deoxyATP, NAD and GTP significantly increased IP3 levels whereas ADP beta S, 2MeSATP, NADP, alpha, beta MeATP, beta, gamma MeATP and ATP alpha S had only a minor, non-significant effect. Irrespective of their potency to increase IP3, all agonists were full glycogenolytic agonists and they all increased cytosolic calcium. With ATP and NAD, IP3 increasing agonists, and 2MeSATP and ADP beta S, non-IP3 increasing agonists, we found that the initial calcium response appeared to be an 'all or none' phenomenon, small amounts of the agonists being either ineffective or equally effective as high amounts. The minimal amount of an agonist needed to initiate a calcium increase and to promote glycogenolysis was very similar. In the absence of extracellular calcium, both groups of purinergic agonists (tested with ATP and 2MeSATP) were equally able to release calcium from intracellular stores. Cells with emptied intracellular calcium stores rapidly took up extracellular calcium upon treatment with ATP or 2MeSATP, the latter being the most potent. It seems therefore that all nucleotides tested increased cytosolic calcium and activated phosphorylase in a very similar way but some nucleotides had no effect on the levels of IP3.

Animals↗
PubMed1995

Demonstration of a glycogen/glucose 1-phosphate cycle in hepatocytes from fasted rats. Selective inactivation of phosphorylase by 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride.

In search for a nonmetabolized, superior glucose analogue to study the mechanism of glucose-induced glycogen synthesis, we have tested 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride, which inhibits muscle phosphorylase beta 10-fold better than dose glucose (Street, I.P., Armstrong, C.R., and Withers, S.G. (1986) Biochemistry 25, 6021-6027). In a gel-filtered liver extract, 0.6 mM analogue and 10 mM glucose equally accelerated the inactivation of phosphorylase and shortened the latency before the activation of glycogen synthase. The analogue was not measurably defluorinated or phosphorylated by intact hepatocytes, as monitored by 19F NMR. When added to isolated hepatocytes, 10 mM analogue inactivated phosphorylase more extensively than did 50 mM glucose, but unlike glucose, it did not result in the activation of glycogen synthase. Therefore, the binding of glucose to phosphorylase alpha can account for the inactivation of phosphorylase, but the metabolism of glucose (probably to Glc-6-P) appears to be required to achieve activation of glycogen synthase. The livers of overnight-fasted, anesthetized mice contained appreciable amounts of both phosphorylase alpha and glycogen synthase alpha, without net glycogen accumulation. Likewise, hepatocytes isolated from fasted rats and incubated with 10 mM glucose contained 41% of phosphorylase and 32% of glycogen synthase in the alpha form, and these values remained stable for 1 h, while glycogen accumulated at only 22% of the rate expected from the glycogen synthase activity. The addition of 10 mM analogue decreased phosphorylase alpha to 10% without significant change in glycogen synthase alpha (38%), but with a 4-fold increased rate of glycogen accumulation. These findings imply that synthase alpha is fully active in the liver of the fasted animal and that the absence of net glycogen synthesis is due to continuous glycogenolysis by phosphorylase alpha.

Animals↗
PubMed1993

Regulation of glycogen phosphorylase activity in isolated human hepatocytes.

Hepatocytes were isolated from human liver tissue by a two-step perfusion technique. They were treated with vasopressin, angiotensin, ATP and phenylephrine, which are known to be Ca(2+)-mediated glycogenolytic agents in rat liver tissue, and as a control, they were treated with the cyclic AMP-mediated hormones glucagon and isoproterenol. All agonists induce a time-dependent activation of glycogen phosphorylase. Glucagon and isoproterenol induce a somewhat higher degree of phosphorylase activation compared with vasopressin, angiotensin, ATP and phenylephrine, which all increase inositol tris-phosphate levels and have no effect on the cyclic AMP levels. The total activity of glycogen phosphorylase (a + b), amounting to 30 to 35 mU/mg protein, is found to be much lower than that found in rat liver tissue. Because only minor differences could be found, we conclude that the regulation of glycogen phosphorylase in human liver tissue is basically the same as that found in rat liver tissue.

Adenosine Triphosphate↗
PubMed1993

Characterization of the effects of adenosine 5'-[beta-thio]-diphosphate in rat liver.

1. In rat liver cells micromolar concentrations of adenosine 5'-[beta-thio]diphosphate (ADP beta S), activate glycogen phosphorylase by an adenosine 3':5'-cyclic monophosphate (cyclic AMP)- independent mechanism. 2. As with adenosine 5'-triphosphate (ATP), ADP beta S also inhibits the rise in cyclic AMP after glucagon. 3. Cytosolic Ca2+ measured in single cells is rapidly increased with a pattern similar for ADP beta S and for ATP. 4. At variance with ATP, ADP beta S hardly increases inositol 1,4,5-trisphosphate (IP3) levels. 5. Phorbol myristic acetate, which inhibits only slightly the glycogenolytic effect of ATP, almost completely abolishes this effect of ADP beta S. 6. With adenosine 5'-[beta-[35S]thio]diphosphate (ADP beta[35S]) as radioligand, we detected specific purinoceptors on rat liver plasma membranes. Binding consists of a major binding component with KD = 0.7 microM and Bmax = 51 pmol mg-1 of protein, probably mediating the activation of glycogen phosphorylase, and a minor high affinity, low capacity binding component with no obvious function. 7. It is concluded that the differences in biological effects between ATP and ADP beta S may involve different receptors and/or different transduction mechanisms and that ADP beta[35S] can be used to detect the specific binding sites for ADP beta S.

Adenosine Diphosphate↗
PubMed1992

Extracellular ATP and UTP exert similar effects on rat isolated hepatocytes.

1. Extracellular UTP and ATP show obvious similarities in their control of several metabolic functions of rat isolated hepatocytes. 2. They have a similar time-course and concentration-dependency for the activation of glycogen phosphorylase, the generation of inositol trisphosphate (IP3), the inhibition of glycogen synthase and the lowering of adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels. 3. There is a similar synergism of the nucleotides with glucagon in activating phosphorylase. 4. They undergo a similar inhibition by phorbol myristic acid of their glycogenolytic effect. 5. The ATP and UTP effect on IP3 levels are not additive. 6. It is tentatively concluded that UTP and ATP use a common receptor.

Adenosine Triphosphate↗
PubMed1991

Characterization of the biological effects of 2-methylthio-ATP on rat hepatocytes: clear-cut differences with ATP.

1. In several tissues, 2-methylthio adenosine triphosphate (2MeSATP) is a very potent P2y-purine agonist. In rat hepatocytes, 2MeSATP half-maximally activated glycogen phosphorylase at 20 nM and was therefore about 25 times more effective than ATP (Ka 0.5-0.8 microM). This strong glycogenolytic potency of 2MeSATP suggests on its own the presence of P2Y-purinoceptors in liver. 2. Displacement of the radioligand ATP alpha[35S] from its receptor however occurred at much higher concentrations of 2MeSATP than was anticipated on the basis of its glycogenolytic potency. 3. The interaction of 2MeSATP with the receptor, characterized with ATP alpha[35S] as radioligand, cannot be considered as a pure competitive interaction. 4. 2MeSATP did not share the ability of ATP to counteract the effect of glucagon on the adenosine 3':5'-cyclic monophosphate levels. 5. 2MeSATP barely increased the levels of inositol trisphosphate (IP3). 6. The glycogenolytic effect of 2MeSATP was completely abolished by pretreatment of the hepatocytes with phorbol myristic acetate. 7. It is tentatively concluded that 2MeSATP and ATP are interacting with different P2 purinoceptors.

Adenosine Triphosphate↗
PubMed1990

Characterization of the purinoceptors present in rabbit and guinea pig liver.

Micromolar concentrations of ATP induced a cAMP-independent glycogenolytic response in rabbit and guinea pig hepatocytes. With ATP alpha[35S] (adenosine 5'-[alpha-[35S]thio]triphosphate) as radioligand, we detected the presence of specific purinoceptors on hepatocytes and liver plasma membranes of both species. We determined a Kd value of 0.28 microM and a Bmax of 4.8 pmol/10(6) cells for rabbit hepatocytes and a Kd of 0.25 microM and a Bmax of 7.0 pmol/10(6) cells for guinea pig hepatocytes. The Kd values with purified plasma membranes from rabbit and guinea pig liver, were respectively 0.2 and 0.1 microM whereas the Bmax values were respectively 71 and 47 pmol/mg of protein. These purinoceptors belong to the P2Y-subclass as is evidenced by the high degree of similarity which exists between the binding affinities of several ATP analogues to either rabbit or guinea pig liver plasma membranes and rat liver plasma membranes, previously shown to possess P2Y-purinoceptors.

Adenosine Triphosphate↗
PubMed1989

Characterization of purinoceptors present on human liver plasma membranes.

Using ATP alpha 35S as radioligand, we have detected the presence of specific purinoceptors on human liver plasma membranes. They are characterized by a Kd value of 0.19 microM and a Bmax of 24 pmol/mg membrane protein. These purinoceptors belong to the P2Y subclass as demonstrated by the high degree of similarity with rat liver purinoceptors, previously shown to be P2Y [(1986) Biochem. J. 240, 367-371] and known to be involved in the control of liver glycogenolysis.

Adenosine Diphosphate↗
PubMed1989

Lack of V1 vasopressin receptors in rabbit hepatocytes.

Vasopressin does not induce glycogenolysis in rabbit hepatocytes; glucagon, angiotensin, phenylephrine and ATP are as potent as with rat hepatocytes, whereas isoprenaline is nearly 10000 times more potent in the rabbit. Binding studies of [3H]vasopressin reveal the complete absence of specific vasopressin receptors on rabbit liver plasma membranes. We verified that vasopressin acts as an antidiuretic and vasopressor agent in the rabbit. We conclude that there is a selective lack of V1 vasopressin receptors in rabbit liver.

Animals↗
PubMed1989

The angiotensin II receptor of rabbit liver: characterization in isolated hepatocytes and effect of GTP.

A homologous population of specific angiotensin II receptors is present on the cell surface of isolated rabbit hepatocytes. The binding characteristics of [3H]angiotensin II to the cells were: association rate constant (K+1) 0.08 l/nmol per min and dissociation rate constant (K-1) 1.9/min, yielding a dissociation constant (Kd) of 24 nmol/l. A very similar Kd (32 nmol/l) has been derived from saturation binding data which indicate a maximal binding capacity of about 200,000 sites/cell. Analysis of the association binding data to purified liver plasma membranes indicated a Kd of 6 nmol/l in the absence and 30 nmol/l in the presence of GTP. Dissociation was clearly dependent upon the presence of the nucleotide, which shifted the K-1 from 0.12/min to 0.42/min. The studied binding sites are very likely to be involved in the glycogenolytic action of angiotensin II, since a highly significant correlation was established between the biological activity (activation of glycogen phosphorylase) and the binding affinity of a series of agonistic analogues. The reported characteristics of the rabbit hepatic angiotensin II receptors show much similarity with those of rat liver.

Angiotensin II↗
PubMed1988

Involvement of a plasma membrane phosphodiesterase in the negative control of cyclic AMP levels by vasopressin in rat hepatocytes.

Vasopressin has been shown previously to lower the glucagon-induced increase of cyclic AMP levels in isolated rat hepatocytes by way of an enhanced phosphodiesterase (EC 3.1.4.17) activity. Five phosphodiesterase inhibitors were tested for their ability to prevent vasopressin from lowering cyclic AMP levels in intact hepatocytes and for their inhibitory effect in vitro on soluble and particulate phosphodiesterase activities partially purified from hepatocytes. Three soluble activities have been separated by DEAE-cellulose chromatography: a phosphodiesterase hydrolyzing both cyclic AMP and cyclic GMP, a form stimulated by cyclic GMP and a cyclic AMP-specific activity. The absence of any statistically significant correlation between the in vivo (in intact cells) and the in vitro (on isolated phosphodiesterases) potencies of the inhibitors does not support a role for the cytosolic phosphodiesterases in mediating the vasopressin-induced decrease in cyclic AMP levels. No statistically significant correlation was observed between the inhibition of the vasopressin effect on cyclic AMP accumulation and the inhibition of phosphodiesterase activity either associated with the native plasma membranes or solubilized from these membranes with 0.4 M NaCl. In contrast, a statistically significant correlation was observed between the degree of inhibition of the vasopressin effect in the intact cells and the degree of inhibition of the intrinsic phosphodiesterase still associated with the plasma membranes after high-salt treatment. These data indicate that a phosphodiesterase activity integral to the plasma membrane is very likely involved in the negative control of cyclic AMP levels by vasopressin.

Animals↗
PubMed1988

Periportal and perivenous hepatocytes respond equally to glycogenolytic agonists.

We have used the technique of short-term infusion with digitonin to obtain hepatocytes originating either from the periportal or the perivenous zone of the liver acinus [(1985) Biochem. J. 229, 221-226]. Total glycogen phosphorylase content and sensitivity to cyclic AMP-dependent and calcium-mediated glycogenolytic agonists were very similar for both cell sub-populations and did not differ from the values obtained for control cells. We conclude therefore that there is an apparent absence of metabolic zonation as far as receptor-mediated glycogenolysis and glycogenolytic potency is concerned.

Adenosine Triphosphate↗
PubMed1986

Characterization of the liver P2-purinoceptor involved in the activation of glycogen phosphorylase.

Evidence has been presented for the existence in rat liver of P2-purinoceptors which are involved in the control of glycogenolysis. Isolated rat hepatocytes and purified liver plasma membranes have been used to study the binding of the ATP analogue adenosine 5'-[alpha- [35S]thio]triphosphate (ATP alpha [35S]) to these postulated P2-purinoceptors. The nucleotide analogue behaves as a full agonist for the activation of glycogen phosphorylase in isolated hepatocytes, 0.3 microM being required for half-maximal activation. Specific binding of ATP alpha [35S] to hepatocytes and plasma membranes occurs within 1 min and is essentially reversible. The analysis of the dose-dependency at equilibrium indicates the presence of binding sites with Kd of 0.23 microM with hepatocytes and Kd of 0.11 microM with plasma membranes. The relative affinities of 10 nucleotide analogues were deduced from competition experiments for ATP alpha [35S] binding to hepatocytes, and these correlated highly with their biological activity (activation of glycogen phosphorylase in hepatocytes). For all the agonists, binding occurs in the same concentration range as the biological effect. These data clearly suggest that the detected binding sites correspond to the physiological P2-purinoceptors involved in the regulation of liver glycogenolysis. The rank order of potency of some ATP analogues suggests that liver possesses the P2Y-subclass of P2-purinoceptors.

Animals↗
PubMed1985

An assessment of the importance of intralysosomal and of alpha-amylolytic glycogenolysis in the liver of normal rats and of rats with a glycogen-storage disease.

Mechanisms of glycogenolysis have been investigated in a comparative study with Wistar rats and gsd rats, which maintain a high glycogen concentration in the liver as a result of a genetic deficiency of phosphorylase kinase. In Wistar hepatocytes the rate of glycogenolysis, as modulated by glucagon and by glucose, was proportional to the concentration of phosphorylase a. In suspensions of gsd hepatocytes the rate of glycogenolysis was far too high as compared with the low level of phosphorylase a; in addition, only a minor fraction of the glycogen lost was recovered as glucose and lactate, owing to the accumulation of oligosaccharides. When the gsd hepatocytes were incubated in the presence of an inhibitor of alpha-amylase (BAY e 4609) glycogenolysis and the formation of oligosaccharides virtually ceased; the production of glucose plus lactate, already modest in the absence of BAY e 4609, was further decreased by 40%, owing to the suppression of a pathway for glucose production by the successive actions of alpha-amylase and alpha-glucosidase. Evidence was obtained that gsd hepatocytes are more fragile, and that amylolysis of glycogen occurred in damaged cells and/or in the extracellular medium. This may even occur in vivo, since quick-frozen liver samples from anesthetized gsd rats contained severalfold higher concentrations of oligosaccharides than did similar samples from Wistar rats. However, administration of a hepatotoxic agent (CCl4) caused hepatic glycogen depletion in Wistar rats, but not in gsd rats. The administration of phloridzin and of vinblastine, which have been proposed to induce glycogenolysis in the lysosomal system, did not decrease the hepatic glycogen level in gsd rats. Taken together, the data indicate that only the phosphorolytic degradation of glycogen is metabolically important, and that alpha-amylolysis is an indication of an increased fragility of gsd hepatocytes, which becomes prominent when these cells are incubated in vitro.

Animals↗
PubMed1985

P2-purinergic control of liver glycogenolysis.

Purinergic agonists cause a dose-dependent activation of glycogen phosphorylase in isolated rat hepatocytes. Half-maximally effective concentrations are 5 X 10(-7)M for ATP, 2 X 10(-6)M for ADP, and about 5 X 10(-5) M for AMP and adenosine. This potency series indicates the presence of P2-purinergic receptors. The mode of action of ATP appears to be identical with that of the Ca2+-dependent glycogenolytic hormones angiotensin, vasopressin and alpha 1-adrenergic agonists. (1) They all require Ca2+ for phosphorylase activation; (2) they do not increase cyclic AMP levels; (3) they are susceptible to heterologous desensitization by vasopressin and phenylephrine; (4) they lower cyclic AMP concentrations in hepatocytes stimulated by glucagon, most probably mediated by an enhanced phosphodiesterase activity.

Adenine Nucleotides↗
PubMed1984

Vasopressin and angiotensin control the activity of liver phosphodiesterase.

Vasopressin and angiotensin are able to lower the glucagon-induced increase of cyclic AMP levels in isolated hepatocytes. Results presented are in favour of an enhanced phosphodiesterase activity to account for this cyclic AMP lowering effect. In particular, vasopressin prevents exogenous cyclic AMP from activating glycogen phosphorylase: in the presence of phosphodiesterase inhibitors, the hormone becomes unable to decrease glucagon-induced cyclic AMP levels. This anti-glucagon effect of vasopressin and angiotensin might be physiologically more important than their glycogenolytic effect; indeed, the latter is very transient in nature and, in addition, requires higher hormone concentrations [Bréant, Keppens & De Wulf (1981) Biochem. J. 200, 509-514] than those needed for the anti-glucagon effect, as reported here.

Angiotensin II↗
PubMed1982

The liver angiotensin receptor involved in the activation of glycogen phosphorylase.

Specific angiotensin binding to rat hepatocytes and purified liver plasma membranes was measured by using biologically active [(3)H]angiotensin (sp. radioactivity 14Ci/mmol). The kinetic parameters for angiotensin binding to hepatocytes are: K(+1) (association rate constant). 100mum(-1).min(-1); K(-1) (dissociation rate constant), 2min(-1); K(d) (dissociation constant). 30nm; maximal binding capacity, 0.42pmol/10(6) cells or 260000 sites/cell. Angiotensin binding to membranes is profoundly affected by GTP (0.1mm) and NaCl (100mm); these regulatory compounds greatly enhance both the rate of association and of dissociation and also the extent of dissociation. K(d) amounts to 10nm in the presence of GTP+NaCl and to 1.5nm in their absence; maximal binding capacity is 0.70pmol/mg of protein, both with or without GTP+NaCl. The relative affinities of 11 angiotensin structural analogues were deduced from competition experiments for [(3)H]angiotensin binding to hepatocytes and to membranes (in the latter case, GTP + NaCl were not included, in order to study the higher affinity state of the receptor). These are highly correlated with their biological activity (activation of glycogen phosphorylase in hepatocytes). Binding to membranes occurs in the same concentration range as the biological effect. On the other hand, the existence of numerous spare receptors is suggested by the observation that binding of the agonists to hepatocytes requires 25-fold higher concentrations than those needed for their biological activity. These data clearly suggest that the detected binding sites correspond to the physiological receptors involved in the glycogenolytic action of angiotensin on rat liver.

Angiotensin II↗